Autopsy report · NCT00924781
A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12)
Cause of deathNo reason given
Life of this trial
- Ran for about 11 months before it stopped.
- 39 participants enrolled.
- Results were posted on the registry 1 year 10 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Merck Sharp & Dohme LLC
- Sponsor type
- Industry
- Conditions
- Anemia; Chronic Kidney Disease
- Interventions
- MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline; MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline; MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline
- Participants
- 39
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.